Virtue® SAB in the Treatment of Coronary ISR Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 740 participants.

Also called NCT07045194

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 740 participants (planned count) (from the registry)
Sponsor
Orchestra BioMed, Inc (from the registry)
Registry
  • NCT NCT07045194
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07045194. Randomized; single masking; primary purpose treatment. Start 2025-10-20 (actual); primary completion 2028-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Virtue® SAB in the Treatment of Coronary ISR Trial
Intervention (Device)
Virtue Sirolimus AngioInfusion Balloon
Intervention (Device)
AGENT™ Paclitaxel Drug-Coated Balloon
Lead sponsor
Orchestra BioMed, Inc (class: industry)

Record details

Record id
cardio:ct-nct07045194
Content hash
332b01a1fb1198ed5e191a634ea8a09e0756410c86cd8c6dd3ce7bfb4df56b7c